Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
AVAnteris Technologies Global Corp. logo

Anteris Technologies Global Corp. (AVR)

NASDAQ Global Market · Currency in USD
$5.87 ▼ -0.13 (-2.17%)
At close: Oct 23, 4:00 PM ET. Market closed.
$5.82 ▼ -0.05 (-0.78%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$6.00
Open
$6.00
Day's Range
$5.86 – $6.09
52 Week Range
$3.30 – $11.06
Volume
901,775
Avg. Volume
1,124,834
Market Cap
$572.08M
Beta (5Y Monthly)
0.73
PE Ratio (TTM)
--
EPS (TTM)
-$1.06
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$10.00

Profile: Anteris Technologies Global Corp.

Sector
Healthcare
Industry
Medical - Devices
Full-time employees
174
CEO
Wayne Geoffrey Paterson

Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$0.31 · Revenue est. $2.75M
DateEst.Actual
Aug 11, 2026-$0.21-$0.30Miss
May 12, 2026-$0.27-$0.28Miss
Mar 11, 2026-$0.50-$0.74Miss
Nov 10, 2025-$0.54-$0.62Miss
Aug 12, 2025-$0.55-$0.58Miss
May 13, 2025-$0.49-$0.61Miss

Analyst view

Consensus price target
$10.00 ▲ +70.4%
Range $10.00 – $10.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on AVR and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.